Millendo Therapeutics Inc (NASDAQ:MLND) – Analysts at Svb Leerink lowered their Q2 2019 earnings estimates for shares of Millendo Therapeutics in a note issued to investors on Wednesday, May 15th, Zacks Investment Research reports. Svb Leerink analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.81) for the quarter, down from their previous forecast of ($0.76). Svb Leerink also issued estimates for Millendo Therapeutics’ Q3 2019 earnings at ($0.84) EPS, Q4 2019 earnings at ($0.86) EPS, FY2019 earnings at ($3.29) EPS, FY2020 earnings at ($3.39) EPS, FY2021 earnings at ($3.57) EPS and FY2022 earnings at ($3.30) EPS.
A number of other analysts also recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Millendo Therapeutics in a report on Wednesday, March 13th. They issued a “buy” rating and a $22.00 target price on the stock. ValuEngine raised shares of Millendo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 20th. Finally, Zacks Investment Research raised shares of Millendo Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Thursday, April 4th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.25.
Millendo Therapeutics (NASDAQ:MLND) last released its earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.08). Millendo Therapeutics had a negative return on equity of 52.20% and a negative net margin of 10,128.37%.
Several institutional investors have recently added to or reduced their stakes in MLND. Morgan Stanley grew its position in Millendo Therapeutics by 749.4% during the first quarter. Morgan Stanley now owns 3,041 shares of the company’s stock valued at $46,000 after purchasing an additional 2,683 shares in the last quarter. Citigroup Inc. grew its position in Millendo Therapeutics by 6,052.5% during the first quarter. Citigroup Inc. now owns 6,091 shares of the company’s stock valued at $91,000 after purchasing an additional 5,992 shares in the last quarter. Geode Capital Management LLC purchased a new position in Millendo Therapeutics during the fourth quarter valued at approximately $113,000. BlackRock Inc. purchased a new position in Millendo Therapeutics during the fourth quarter valued at approximately $203,000. Finally, Worth Venture Partners LLC purchased a new position in Millendo Therapeutics during the fourth quarter valued at approximately $206,000. 44.07% of the stock is currently owned by institutional investors and hedge funds.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
See Also: What is a Fibonacci Channel?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.